



August 23, 2016

Press release

Mitsubishi Tanabe Pharma Corporation

**Application filed in Japan for  
type 2 diabetes mellitus treatment agent combination drug  
- Combination of selective DPP-4 inhibitor TENELIA<sup>®</sup> Tablets  
and SGLT2 inhibitor CANAGLU<sup>®</sup> Tablets -**

**Osaka, Japan, August 23, 2016**—Mitsubishi Tanabe Pharma Corporation (President & Representative Director: Masayuki Mitsuka) announced today that it has filed an application with the Ministry of Health, Labour and Welfare for a combination drug that combines selective DPP-4 inhibitor TENELIA<sup>®</sup> Tablets (generic name: teneligliptin) and SGLT2 inhibitor CANAGLU<sup>®</sup> Tablets (generic name: canagliflozin). The application is for an indication of type 2 diabetes mellitus.

TENELIA<sup>®</sup> Tablets selectively inhibit the activity of dipeptidyl peptidase-4 (DPP-4), an enzyme that inactivates glucagon-like peptide-1 (GLP-1), a hormone excreted from the gastrointestinal tracts in response to food ingestion. In this way, TENELIA<sup>®</sup> Tablets increase insulin release and suppress glucagon release, thereby lowering blood-glucose levels.

CANAGLU<sup>®</sup> Tablets inhibit sodium glucose co-transporter 2 (SGLT2), a transporter involved in the reabsorption of glucose in the proximal renal tubules of the kidneys; suppress the reabsorption of glucose; and promote the excretion of excessive glucose into the urine, and as a result, lower blood glucose. Both of these drugs originated in Japan and were discovered by Mitsubishi Tanabe Pharma.

For this application, the efficacy, safety, and good tolerability of this combination drug were confirmed in clinical trials targeting examples of insufficient effectiveness of TENELIA<sup>®</sup> Tablets and/or CANAGLU<sup>®</sup> Tablets. In addition, TENELIA<sup>®</sup> Tablets and CANAGLU<sup>®</sup> Tablets are both oral agents administered once per day, and this drug combines two tablets into one. As a result, good blood glucose control is expected due to the further enhancement of convenience for patients and the improvement of medication adherence.

Moving forward, Mitsubishi Tanabe Pharma will leverage the drug discovery capabilities that it utilized to discover TENELIA<sup>®</sup> Tablets and CANAGLU<sup>®</sup> Tablets to provide new choice in the treatment of type 2 diabetes mellitus and make a further contribution to the treatment of patients with diabetes.

⟨⟨For Details, Contact the Following Section⟩⟩  
Corporate Communications Department  
Tel +81-6-6205-5211